Carman Alenson - Oct 19, 2022 Form 3 Insider Report for Prime Medicine, Inc. (PRME)

Role
Interim Chief Financial Officer and Chief Accounting Officer. Exhibit 24 - Power of Attorney
Signature
/s/ Carman Alenson
Stock symbol
PRME
Transactions as of
Oct 19, 2022
Transactions value $
$0
Form type
3
Date filed
10/19/2022, 08:05 PM
Previous filing
Jun 23, 2021
Next filing
Apr 4, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding PRME Stock Option (right to buy) Oct 19, 2022 Common Stock 129K $3.67 Direct F1
holding PRME Stock Option (right to buy) Oct 19, 2022 Common Stock 6.43K $3.67 Direct F2
holding PRME Stock Option (right to buy) Oct 19, 2022 Common Stock 16.1K $10.92 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares underlying this option vested and became exercisable on August 2, 2022, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
F2 1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of October 27, 2021, subject to the Reporting Person's continued service on each such vesting date.
F3 1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of January 24, 2022, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

Interim Chief Financial Officer and Chief Accounting Officer. Exhibit 24 - Power of Attorney